What is adenocarcinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Adenocarcinoma

Adenocarcinoma is a malignant epithelial tumor characterized by glandular or acinar differentiation, papillary structures, and cytoplasmic mucin vacuoles. 1

Core Pathologic Definition

Adenocarcinoma represents a broad category of cancers arising from glandular epithelial cells that can occur in virtually any organ system. The defining microscopic features include:

  • Glandular or acinar differentiation visible at the light microscopic level, forming recognizable gland-like structures 1
  • Papillary architectural patterns with finger-like projections of tumor cells 1
  • Cytoplasmic mucin vacuoles within malignant cells 1
  • Invasion through the basement membrane, distinguishing it from in situ disease 1

The diagnosis can be supported by special stains for mucin or immunohistochemical markers of ductal differentiation such as cytokeratin 19. 1

Histologic Subtypes and Grading

Adenocarcinomas are classified into multiple histologic subtypes depending on their architectural patterns:

Common Subtypes

  • Acinar adenocarcinoma: Forms well-defined glandular structures 1
  • Papillary adenocarcinoma: Characterized by papillary projections 1
  • Micropapillary adenocarcinoma: Small rounded tumor cell clusters within stromal spaces, associated with adverse features including lymphovascular invasion 1
  • Solid adenocarcinoma: Lacks glandular architecture, considered high-grade 1
  • Mucinous adenocarcinoma: Contains >50% extracellular mucin pools with malignant glands or individual tumor cells 1
  • Signet-ring cell adenocarcinoma: >50% of tumor shows signet-ring morphology with intracytoplasmic mucin displacing nuclei, associated with worse stage-for-stage survival 1

Grading System

Adenocarcinomas are graded based on architectural and cytologic features: 1

  • Well-differentiated (Grade 1): Well-defined glands with minimal nuclear pleomorphism, few mitoses 1
  • Moderately differentiated (Grade 2): Disorganized growth with less defined glands, increased nuclear pleomorphism and mitoses 1
  • Poorly differentiated (Grade 3): Small poorly defined glands, individual infiltrating cells, solid areas, prominent nuclear pleomorphism, frequent mitoses 1

Histologic grading provides prognostic information regarding likelihood of nodal metastases and overall survival. 1

Organ-Specific Characteristics

Lung Adenocarcinoma

The most common form of lung cancer, characterized by peripheral location and often associated with a desmoplastic stromal response. 1 Subtypes include acinar, papillary, micropapillary, and solid patterns, frequently presenting as composite subtypes. 1

Colorectal Adenocarcinoma

Almost all colorectal cancers are adenocarcinomas, most classified as "not otherwise specified" (NOS). 1 Specific subtypes carry distinct prognostic implications, with signet-ring cell variant showing worse survival and medullary carcinoma demonstrating better prognosis. 1

Pancreatic Adenocarcinoma

Invasive ductal adenocarcinoma represents the vast majority of pancreatic malignancies, characterized by ductal differentiation and intense desmoplastic reaction. 1 Subtypes include tubular, adenosquamous, colloid (mucinous noncystic), and medullary variants. 1

Cervical Adenocarcinoma

Accounts for 10-25% of cervical cancers with rising incidence, often HPV-associated (particularly HPV-18), presenting diagnostic challenges due to endocervical location. 2, 3, 4 Shows greater propensity for lymph node and distant metastases compared to squamous cell carcinoma. 2, 3

Clinical Significance

Desmoplasia (cellular fibroinflammatory response) characteristically accompanies invasive adenocarcinomas, representing the host stromal response rather than pre-existing scar tissue. 1 This feature is particularly prominent in pancreatic, breast, and lung adenocarcinomas. 1

The heterogeneity of adenocarcinomas—both between different organ sites and within individual tumors—represents a major clinical challenge affecting treatment response and prognosis. 5 Accurate histologic subtyping and grading are essential for appropriate treatment planning and prognostic stratification. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Adenocarcinoma of the uterine cervix: particularities in diagnosis and treatment].

Journal de gynecologie, obstetrique et biologie de la reproduction, 2013

Research

Contemporary Review of Adenocarcinoma of the Cervix.

Current treatment options in oncology, 2024

Related Questions

What are the diagnostic and treatment options for a patient with adenocarcinoma?
What is the treatment plan for adenocarcinoma, considering the 4Rs (Right drug, Right dose, Right route, and Right time) of chemotherapy?
What is the best course of action for a patient with cervical adenocarcinoma (cervical cancer) presenting with abdominal pressure and pain, post-coital spotting, dyspareunia (painful intercourse), hematuria (red blood cells in urine), back pain, and urinary urgency?
What is the recommended initial approach for a 2.4cm right lower lobe adenocarcinoma?
What is the recommended treatment approach for a patient with carcinoma of the cervix who is a candidate for the Interlace trial?
What is the recommended overview, pre‑operative preparation, surgical technique, postoperative care, potential complications, and alternative options for distal femur replacement in patients over 65 with unreconstructable distal femoral pathology?
How should I evaluate and manage an elevated mean corpuscular volume (MCV)?
What is the appropriate potassium replacement dosing for an adult with a serum potassium of 2.8 mEq/L?
What is the recommended dosing frequency and treatment duration for ophthalmic tobramycin 0.3% eye drops (or ointment) and for systemic therapy in severe Pseudomonas infection?
What is the appropriate next step in managing a 67-year-old man with a newly detected prostate-specific antigen of 4.37 ng/mL and no prior baseline?
What is the recommended management for a patient with GAD‑7 11/21 (moderate anxiety), PHQ‑9 26/27 (severe depression) and QoL 3/16 (very poor quality of life)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.